In 2014, the total economic burden of
vision loss and blindness in the United States was $145 billion.
—National Alliance for Eye
and Vision Research
DID YOU KNOW?
Tumeric, a commonly used spice
found in many people’s pantries,
can be effective in treating the
blinding disease retinitis
—National Eye Institute,
National Institutes of Health
In clinical trials,
treatment for LCA restores sight in patients who
were nearly blind. Today, more than 40 people
have received the life-changing treatment.
2011 Oxford BioMedica, a Foundation partner, launches clinical trials for
gene therapies targeting AMD, Stargardt disease
and Usher syndrome. Also, the FDA approves
Eylea®, a drug used to treat AMD.
2012 The company QLT’s retinoid- replacement therapy improves
vision in a clinical trial for people with RP
2013 The FDA approves a “bionic retina” enabling those who are completely
blind to see light and shadows. Called the Argus
II, it received FFB funding in the early stages of
2014 During an early clinical trial for a choroideremia gene therapy,
patients report improved vision. The trial was
made possible by pre-clinical research funded
by FFB for two decades.
2015 Spark Therapeutics, the company responsible for the LCA gene
therapy, launches a Phase I clinical trial for a
gene therapy targeting choroideremia.
The Argus II